Crucell and Bioceros sign licensing agreement
The license agreement with the Netherlands based company Bioceros covers the production of monoclonal antibodies. Financial details of the agreement were not disclosed. Star technology is a production
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.